Monoacylglycerol lipase modulators

A method of treating a patient suffering from or diagnosed with a condition selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression and bipolar disorder, comprising administering to a patient in need thereof a compound, having the structure of Formula (I):

• wherein
• R2 is selected from the group consisting of:
• (a)
• (b) 6-membered heteroaryl selected from the group consisting of:
• pyridazin-4-yl;
• pyrazin-2-yl;
• pyrimidinyl;
• pyrimidinyl substituted with C1-4alkyl or OC1-4alkyl;
• and pyridinyl, wherein the pyridinyl is substituted with one or two substituents each independently selected from the group consisting of:
• halo, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, C3-6cycloalkyl, NH2, CN, N(CH3)2,
• (c) 5-membered heteroaryl selected from the group consisting of:
• (d) 5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl selected from the group consisting of:
• (e) 6,6-fused bicyclic heteroaryl selected from the group consisting of:
• and
• (f)
• wherein
• Ra is selected from the group consisting of:
• H, halo, C1-4alkyl, OC1-4alkyl, C1-4haloalkyl and OC1-4haloalkyl;
• Ra1 is selected from the group consisting of:
• C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, N(C═O)CH3, oxazol-2-yl, pyrimidin-2-yl, and 5-membered heteroaryl ring containing two, three, or four nitrogen members, wherein the 5-membered heteroaryl ring is optionally substituted with one Ra member;
• Rb is H or C1-4akyl;
• Rc is H or C1-4haloalkyl;
• Rd is H or halo;
• Rc is selected from the group consisting of:
• H, halo, C1-4akyl, C1-4haloalkyl, OC1-4alkyl, and C3-6cycloalkyl;
• Rf is selected from the group consisting of:
• H, C1-4alkyl, CH2CH2OH, C1-4haloalkyl, cyclopropyl, phenyl, and phenyl substituted with CF3;
• Rg is selected from the group consisting of:
• H, OC1-4alkyl and C1-4haloalkyl;
• Ri is H, halo, C1-4alkyl, C1-4haloalkyl, OH, OC1-4alkyl, OC1-4haloalkyl, C3-6cycloalkyl;
• Rj is selected from the group consisting of:
• H, halo, OCH3, OH, NH2, and NO2;
• R3 is selected from the group consisting of:
• (g) phenyl, wherein phenyl is independently substituted with one, two, or three members selected from the group consisting of:
• halo, C1-4alkyl, C1-4haloalkyl, and OC1-4alkyl;
• (h) 5-(trifluoromethyl)-2-thienyl or 1-methylindo1-2-yl;
• and
• (i) cyclopropyl;
• and
• R4 is C1-4alkyl or C3-4cycloalkyl;
• and pharmaceutically acceptable salts thereof.